FDA Grants Orphan Drug Status to BioXcel’s BXCL701 as Potential AML Treatment
News
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BXCL701, one of BioXcel Therapeutics’ lead immunotherapies for the treatment of acute myeloid leukemia (AML). Orphan drug ... Read more